NCT07392528 2026-02-11
Universal Chimeric Antigen Receptor T-Cell （UCAR T-cell） Therapy Targeting CD19/ BCMA（QT-019C） in Patients With r/ r Neurological Autoimmune Diseases
Tianjin Huanhu Hospital
Phase EARLY_PHASE1 Not yet recruiting
Clinical Trials
10 trialsNCT07337785 2026-01-22
CD19/BCMA-Targeted UCAR-T for Patients With Neurological Autoimmune Diseases
Tongji Hospital
Phase EARLY_PHASE1 Recruiting
NCT06939166 2025-12-15
Universal Chimeric Antigen Receptor T-Cell （UCAR T-cell） Therapy Targeting CD19/B Cell Maturation Antigen （CD19/BCMA） in Patients With r/r Neurological Autoimmune Diseases
Tianjin Huanhu Hospital
Phase EARLY_PHASE1 Recruiting
NCT04431895 2025-09-16
Safety And Efficacy Of Tofacitinib In Patients With Refractory Myasthenia Gravis: A Pilot Study
Huashan Hospital
Phase EARLY_PHASE1 Completed
NCT07058298 2025-09-08
GC012F Injection in the Treatment of Refractory Generalized Myasthenia Gravis(24103)
Tongji Hospital
Phase EARLY_PHASE1 Recruiting
NCT06933563 2025-04-18
UCAR T-cell Therapy Targeting CD19/BCMA in Patients With r/r Myasthenia Gravis
Zhejiang University
Phase EARLY_PHASE1 Not yet recruiting
NCT06485232 2025-01-01
Universal CAR-T Cells in Patients with Refractory Autoimmune Diseases of the Nervous System.
Xuanwu Hospital, Beijing
Phase EARLY_PHASE1 Not yet recruiting
NCT04561557 2024-10-30
CARTinNS
Tongji Hospital
Phase EARLY_PHASE1 Recruiting
NCT03059888 2019-11-22
Trial of Orencia in Patients With Myasthenia Gravis
Johns Hopkins University
Phase EARLY_PHASE1 Terminated
NCT01555580 2012-03-15
A Pilot Study of Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) in Generalized Myasthenia Gravis
Muscular Dystrophy Association
Phase EARLY_PHASE1 Unknown